Archives: Resources

ARC’s own Kristen Hsu presented the most current updates for the clinical trial landscape, with a focus on AL amyloidosis. Kristen also discussed the direction future research.

The webinar concluded with a Q and A session.

Original Presentation Date:
September 13, 2024

Download Kristen’s Slides →

0:00 — Intro

3:32 — What is a Clinical Trial?

9:26 — Should I Participate in a Trial?

12:07 — AL Amyloidosis Treatment Approaches

19:20 — AL Amyloidosis Clinical Trials

20:10 — AQUARIUS (Daratumumab; Monoclonal Antibody)

22:51 — LINKER-AL2 (Linvoseltamab; Bispecific Antibody)

24:48 — ABBV-383 (Bispecific Antibody)

26:56 — NEXICART-2 (NXC-201; CAR-T Cell Therapy)

29:14 — AFFIRM-AL (Birtamimab; Anti-Amyloid Antibody)

32:41 — Future Drug Development

33:52 — Other Clinical Trials

37:38 — How to Find Clinical Trials

40:43 — Q&A Session

42:55 — How do you find clinical trials in the UK?

43:37 — Do AL fibril treatments work for other types of amyloidosis?

44:50 — How is “relapsed” defined?

46:47 — Can you comment on CAEL-101?

48:06 — What is the correlation between amyloidosis and minority ethnic groups?

49:12 — What is t(11;14)?

50:14 — Are there any trials targeting GI involvement?

52:13 — Are imaging studies on MyAmyloidosisPathfinder.org (MAP)? Can you comment on PYP scan in AL amyloidosis?

53:39 — Are there any studies for caregivers and family members?

55:11 — Is the stabilizer being considered for first treatments with other drugs or as maintenance in relapse cases?

56:36 — What is the role of bone marrow transplant in these studies?

58:21 — Is there anything being done for rarer types of amyloidosis?

Contact ARC:

Call +1 (617) 467-5170

Email ARC at support@arci.org